Vitiligo

Israeli researchers find more than five fold risk of developing systemic sclerosis among people with vitiligo.

Nada Elbuluk, MD, and David Rosmarin, MD, discuss the role of the health care provider in helping patients understand their vitiligo and treatment options.

Experts in dermatology share their approaches to communicating with patients about their vitiligo, highlighting family history and genetic awareness.

A recent systematic review on surgical therapies for vitiligo examined surgical therapies such as punch grafting, suction blister epidermal grafting, and cellular grafting techniques

Vitiligo, an autoimmune skin condition that causes depigmentation, can have a large effect on a patient’s quality of life and psychosocial well-being.

Nada Elbuluk, MD, and David Rosmarin, MD, discuss screening patients with vitiligo for common comorbidities.

Nada Elbuluk, MD, and David Rosmarin, MD, provide an overview of vitiligo, its prevalence, and potential triggers.

At the 2022 Fall Clinical Dermatology Conference, 5 practitioners share their best tips for treating their patients

Data demonstrates an increase in the proportion of patients achieving regimentation with longer duration of ruxolitinib cream treatment.

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.

A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.

A case study reviewed an 11-year-old male for loss of pigmentation of the right side of his back and right arm.

At the Skin of Color Update 2022 meeting, Pearl Grimes, MD, shares her thoughts on the recent approval of ruxolitinib cream.

Hilary Baldwin, MD, discusses what's new and exciting at the Skin of Color Update Meeting in NYC

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

Pigmentary disorders of the skin can be the cause of significant psychological distress in affected patients.

Hiring investigators of color, educating and building trust with potential participants, and addressing funding can make clinical trials more diverse.

Frank discussions about managing the disorder can boost patients’ self-esteem and quality of life.

Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.

Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for patients with vitiligo.

At the SPD 2022 47th annual meeting, investigators share data on the treatment of ruxolitinib for this chronic autoimmune disease.

At the SPD 2022 47th Annual Meeting, researchers delve into the safety and practicality of using narrow-band UVB phototherapy on children with vitiligo.

An extraordinary display of posters at this year's Society for Pediatric Dermatology annual conference.

Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.